Christine Ryan, MD, Discusses Phase II Results of Acalabrutinib, Venetoclax, Obinutuzumab in CLL
By Cecilia Brown, Christine Ryan, MD - Last Updated: January 11, 2023Christine Ryan, MD, of the Dana-Farber Cancer Institute, discusses updated results from a multicenter, phase II study of acalabrutinib, venetoclax, obinutuzumab in a population of previously untreated patients with chronic lymphocytic leukemia. Dr. Ryan and colleagues presented the research at the 2022 American Society of Hematology Annual Meeting.
Advertisement
Post Tags:ASH22
Advertisement
Related Posts
New data on immune thrombocytopenia were most prominent but Meeting coverage ranged over several forms of the disease.
Andrew Kuykendall, MD, presented on the status of myelofibrosis treatment in the era of 4 approved JAK inhibitors.
The CARTITUDE-4, KarMMa-3, and DREAMM-7 trials are paving the way for immunotherapy in multiple myeloma.
A panel moderated by Neil Love, MD, explored clinical data to assess these treatment approaches for the various types of NHL.
The several considerations involved with these agent classes make discussions with patients of treatment decisions crucial.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.